Back to search

Article

Pharmacological SOS1 inhibitor BI-3406 demonstrates <i>in vivo</i> anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors

2024-09-22

Abstract excerpt

<h4>ABSTRACT</h4> Resistance to KRAS mut inhibitors frequently arises, warranting further searches for anti-RAS cancer therapies. We evaluated the tolerability and efficacy of SOS1 pharmacological inhibition in comparison to genetic ablation in different KRAS-dependent tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2KO mice, SOS1 pharmacological inhibition by its specific i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2e729a7b-17a7-5f89-81cb-ac45f9e525bc
DOI
10.1101/2024.09.18.613686
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pharmacological SOS1 inhibitor BI-3406 demonstrates <i>in vivo</i> anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumorsDOI 10.1101/2024.09.18.613686
SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity
Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.Semantic proximity
Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinomaSemantic proximity
Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemiaSemantic proximity
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinomaSemantic proximity
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Semantic proximity
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.Semantic proximity
The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.Semantic proximity
Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesSemantic proximity
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.Semantic proximity
Select a neighboring publication to make it the new centre.